Abstract
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have